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The aim of this article is to review rheumatological diseases that are associated with glucocorticoid-induced
osteoporosis or fractures and to perform a critical analysis of the current guidelines and treatment regimens. The
electronic database MEDLINE was searched using the date range of July 1986 to June 2009 and the following search
terms: osteoporosis, bone mineral density, fractures, systemic lupus erythematosus, rheumatoid arthritis, systemic
sclerosis, vasculitis, juvenile rheumatoid arthritis, juvenile idiopathic arthritis and juvenile dermatomyositis.
Osteopenia and osteoporosis respectively account for 1.4 to 68.7% and 5.0 to 61.9% of adult rheumatological
diseases. Among juvenile rheumatological disorders, the frequency of low bone mass ranges from 38.7 to 70%. In
general, fracture rates vary from 0 to 25%. Although glucocorticoid-induced osteoporosis has a high rate of
prevalence among rheumatic diseases, a relatively low number of patients on continuous glucocorticoid treatment
receive adequate diagnostic evaluation or preventive therapy. This deficit in patient care may result from a lack of
clear understanding of the attributed risks by the patients and physicians, the high complexity of the treatment
guidelines and poor patient compliance.
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INTRODUCTION
Glucocorticoids (GC) are frequently used for the manage-
ment of patients with rheumatological diseases. The use of
GC, however, is associated with a variety of adverse effects,
1
including the development of osteoporosis and fractures. In
patients who have received GCs for longer than six months,
the estimated glucocorticoid-induced osteoporosis (GIO)
frequency is 50%.
2 One-third to one-half of long-term GC
users may develop fractures. Furthermore, the risk of
fractures strongly correlates with the daily and cumulative
dose of GC and does not seem to correlate with the specific
underlying disease.
3 The underlying diseases for which GCs
are prescribed, however, usually carry a risk of osteoporo-
sis. The objective of the present study was to review
rheumatic diseases in which GIO fractures have been
described and to perform a critical analysis of the diagnostic
criteria of osteoporosis and low bone mass. In addition, the
current guidelines and treatment barriers for the manage-
ment of GIO will be discussed.
Pathophysiology
The pathogenesis of GIO is multifaceted. Glucocorticoids
have indirect effects on osteoporosis by inhibiting calcium
absorption from the gastrointestinal track and decreasing
the renal tubular reabsorption of calcium and consequentely
secondary hyperparathyroidism. Nevertheless, hyperpar-
athyroidism does not play a central role in the pathogenesis
of GIO, snce the most of patients using chronic GC present
normal levels of serum parathromone. GCs reduce growth
hormone (GH) secretion and may alter the GH/insulin-like
growth factor (IGF)-I axis; however, the serum levels of IGF-
I are normal during osteoporosis, suggesting that alterations
in the GH/IGF-I axis play a minor role in this skeletal
disease. A more important role may be played by skeletal
IGF-I because GCs inhibit IGF-I transcription in osteoblasts.
In addition, GCs inhibit the release of gonadotrophins and
the resulting hypogonadism may contribute to skeletal
disease.
3
Glucocorticoids have direct effects on bone cells. Bone
histomorphometric analyses of biopsies obtained from
patients with GIO reveal decreased bone turnover with a
disproportionate reduction in bone formation. GCs reduce
the replication, differentiation and function of osteoblasts
4
and increase the apoptosis rates of mature cells, thereby
depleting the osteoblastic cell population and inhibiting the
function of mature cells.
3 Furthermore, in the presence of
GCs, bone marrow stromal cells do not differentiate into
osteoblasts; instead, these cells differentiate toward an
adipocyte cell lineage. The underlying mechanism for this
change in cell fate appears to be related to an induction of
CCAAT enhancer binding proteins and possibly by inhibit-
ing Wingless (Wnt)/b-catenin signaling.
3 Moreover, GCs
induce apoptosis in osteocytes and affect the functioning of
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1197these cells. GCs increase the expression of macrophage
colony stimulating factor (M-CSF) and receptor activator of
Nuclear fator kappa beta ( NF-kB) ligand (RANK-L). In
addition, GCs decrease the expression of osteoprotegerin in
stromal and osteoblastic cells. Through these mechanisms,
GCs can induce the formation of osteoclasts and favor bone
resorption. GCs also reduce the rate of apoptosis among
mature osteoclasts.
3
GIO in Rheumatic Diseases
The electronic database MEDLINE was searched using
the date range of July 1986 to June 2009 and the following
search terms: osteoporosis, bone mineral density, fractures,
systemic lupus erythematosus, rheumatoid arthritis, sys-
temic sclerosis, juvenile rheumatoid arthritis, juvenile
idiopathic arthritis and juvenile dermatomyositis. A total
of 17 studies were found regarding systemic lupus
erythematosus, 16 about rheumatoid arthritis and 13 about
juvenile rheumatic diseases. All of these studies included
patients on GC (Tables 1, 2 and 3).
5–50 The definition of
osteoporosis as determined by bone mineral density (T-
score ,-2.5) and osteopenia (T-score ,-1.0 to -2.5) should be
the definition used for postmenopausal women;
51 however,
it is not applicable to GIO because patients on GCs can
fracture at T-scores in the normal or osteopenic range.
Along these lines, the International Society of Clinical
Densitometry recommends the following definition: ‘‘below
the expected range for age’’ for Z-scores lower than -2.0 and
‘‘within the expected range for age’’ for Z-scores above -2.0
for premenopausal women, children and adolescents
instead of osteoporosis/osteopenia for GIO.
52 Never-
theless, published reports use different definitions for
diagnosing GIO, thereby limiting the effectiveness of study
comparisons. For example, the term osteoporosis may not
be used for patients with fractures and a bone mineral
density greater than -2.5.
53
Systemic Lupus Erythematosus
Studies on systemic lupus erythematosus demonstrate
a frequency of osteoporosis from 4.0 to 48.8% and of osteo-
penia from 1.4 to 68.7%.
5–21 Fractures were evalu-
ated in four of these reports, with a frequency of 5.0 to
21.4%.
7,11–13 A negative association between bone mass and
glucocorticoid use was documented in ,60% of these
studies.
5–7,13,15–17,20,21 Other possible associations with low
bone mass in subjects with lupus were the chronicity of the
disease, disease duration, low body mass index and weight,
increased age, habitual drinking, positive serum markers
of inflammation, renal dysfunction, menopause and phy-
sical dysfunction (Table 1).
6–8,10–14,17–18,20
Rheumatoid Arthritis
The frequency of osteoporosis in patients with rheuma-
toid arthritis (RA) ranges from 4 to 24% and the frequency
of osteopenia ranges from 28 to 61.9%.
22,26,32,36 Fractures
were evaluated in four studies out of 16, which showed a
prevalence of osteoporosis of 0 to 25% in patients with
rheumatoid arthritis;
23,28,30,36 however, only two of these
patients exhibited an association with GC use.
23–30 De Nijs
et al., showed that each 1 mg prednisone equivalent increase
in the daily dose of GC increased the risk of vertebral
deformities and symptomatic vertebral fractures in pati-
ents with RA.
30 Glucocorticoid use was associated with
decreased bone mass in 56.2% of subjects with RA.
28,31–35,37
Bone loss was also related to the Disease Activity Score, a
change in the Health Assessment Questionnaire, radiologi-
cal joint damage, age, postmenopausal state, low physical




Some studies have addressed GIO in juvenile idiopathic
arthritis (JIA), which includes juvenile rheumatoid arthritis
(JRA), juvenile chronic arthritis (JCA), juvenile systemic
lupus erythematosus and juvenile dermatomyositis.
38–50
The prevalence of low bone mineral density in children
with rheumatic diseases is difficult to assess because various
studies have used different cut-off points for Z-scores (e.g.,
, 1.0, , 2.0).
41,44–47,50 Recently, the International Society of
Clinical Densitometry defined low bone mineral density as a
Z-score below –2.0 in children and adolescents in an attempt
to standardize clinical data.
52,54 In JIA, an association
between glucocorticoid use and low bone mass was
observed in four out of five studies.
39–41 Santiago et al.,
found a relationship between pulse therapy with methyl-
prednisolone (30 mg/kg per day for at least three days) and
low bone mass in juvenile dermatomyositis.
43 An associa-
tion between glucocorticoid use and low bone mass was
also observed in two studies that evaluated patients with
juvenile systemic lupus erythematosus
47,48 and in a study
that evaluated several juvenile rheumatic diseases.
49 Seven
studies evaluated the prevalence of fractures and only one
42




Several studies have assessed bone mass in patients with
systemic sclerosis;
55–58 however, only two reports included
patients on glucocorticoid therapy.
57,58 These authors did
not find an association between osteoporosis and glucocor-
ticoid use in this disease.
57,58
Systemic Vasculitis
Few studies have addressed GIO in systemic vasculitis
and only polymyalgia rheumatica and giant cell arteritis
have been described.
59–62 The frequency of osteoporosis has
been shown to vary from 14.9 to 85%.
60,61 Vertebral fractures
were analyzed in a study that compared placebo with




There are a number of guidelines regarding the manage-
ment of GIO in patients who are receiving glucocorticoid
treatment or that will be starting this therapy. We have
reviewed the guidelines established by the American
College of Rheumatology (ACR),
63 the Department of
Veterans Affairs Medical Centers (VMACs),
64 the Dutch
Society of Rheumatology (DSR)
65 and the Royal College of
Physicians (RCP).
66 Various similarities among these four
guidelines have been noted (Tables 4 and 5). All of these
guidelines have recognized that even a short duration (3
months) of glucocorticoid use increases the risk of fracture
and they recommend intervention. In addition, they suggest
modification of life style risk factors (smoking cessation or
avoidance, reduction of alcohol consumption if excessive
and performance of weight-bearing physical exercises).
63–66
GIO in rheumatic disease
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1201The Royal College of Physicians’ guidelines also reinforce
the necessity to use the lowest GC dose possible.
66
Barriers in the Management of GIO
Although numerous guidelines for GIO management
have been published, previous studies suggest that a
relatively low percentage of patients who receive contin-
uous glucocorticoid treatment are evaluated or adminis-
tered preventive treatment for GIO. Saag et al., studied more
than 3,000 adult men and women who had undergone long-
term glucocorticoid therapy. These authors found that bone
mineral density testing was performed in 19% of post-
menopausal women and in 6% of women under the age of
50 years.
67 The use of antiosteoporotic medication was most
common among postmenopausal women and its use
approached 50% in this group. In addition, the medical
specialty of the physician providing care influenced both
testing and treatment regimens. Notably, testing rates were
3 to 4 times greater in rheumatology practices than in
internal medicine or family medicine practices.
67,68 There
are several possible explanations for these low compliance
rates with current guidelines. For example, published
guidelines are inconsistent regarding who should be
treated. In addition, the dose and duration of glucocorticoid
therapy are not standardized. Guidelines are also difficult to
implement due to the physician’s focus on the underlying
disease. In select cases, there may be limited access to
densitometry. Furthermore, patients and physicians may
not have a clear perception of the risk of GIO and patients
may not accept treatment. Our findings suggest that
unification of guidelines regarding the glucocorticoid dose
that would require treatment (such as prednisone equiva-
lents $ 5 mg/day for at least 3 months), requirement of
densitometric evaluation (premenopausal women and
patients on GCs) and indication of bisphosphonates for
prevention (postmenopausal women and men) and treat-
ment (T-score , -1.0 or previous fragility fracture in




Because GCs induce an overall negative calcium balance,
adequate calcium and vitamin D supplementation is
important. A Cochrane Database Meta-Analysis concluded
that calcium and vitamin D supplementation should be
started in all patients who are administered glucocorticoids
because of their low toxicity, low cost and the possible
benefit in terms of fracture risk.
70 Vitamin D is a hormone
that increases intestinal calcium absorption and increases its
reabsorption in distal renal tubules. Serum levels of at least
30 ng/mL (82 nmol/L), and optimally of 40–60 ng/mL, of
25-hydroxyvitamin D should be the target treatment regi-
men for GIO management. To achieve these levels, 1,000 to
2,000 IU of oral vitamin D daily may be necessary.
71









GC dose $ 5mg/day $ 5–7.5 mg/day $ 7.5 mg/day Not specified
Indication for calcium
plus vitamin D
Yes Yes Not specified Yes, if:
- low dietary calcium intake





Yes, if: Yes Yes, if: Yes, if:
- GC therapy $
6 months
- GC 7.5–15 mg/day
- premenopausal women
- men , 70 yrs
- , 65 yrs





Not specified Not specified , -2.5 - 1.5
Indication for
bisphosphonate
- Prednisone $ 5
mg/day for $
6 months
- Prednisone . 5 mg/day,
except if BMD is normal
- DXA is not available
- Prednisone . 15 mg/day
- Fracture
- Post-menopausal
- Men . 70 yrs
- . 65 yrs (men and women)
- Previous history of fragility
fracture
GC, Glucocorticoid









GC dose $ 5mg/day Not specified Not specified Not specified
Indication for calcium plus vitamin D Yes Yes Not specified Yes
Indication for densitometric
evaluation before bisphosphonates
Yes Yes Not specified Yes
Indication for bisphosphonate BMD ,-1.0 - low BMD
- history of fracture
Not specified BMD ,-1.5 or a reduction
in BMD . 4% after 1 year
GC, Glucocorticoid; BMD, bone mineral density
GIO in rheumatic disease
Pereira RMR et al.
CLINICS 2010;65(11):1197-1205
1202Bisphosphonates are indicated for the prevention and
treatment of GIO and most guidelines recommend the use
of these drugs.
63–66 The prevention and treatment goals of
bisphosphonate use are stabilized or increased bone mineral
density, as well as reduced frequency of fractures. A study
using risedronate showed a decrease in vertebral fractures
after one year of treatment.
72 Currently, alendronate (70 mg/
week or 10 mg/day) and risedronate (35 mg/week or 5 mg/
day) are the only oral antiresorptive drugs that are
recommended in GIO. Recently, zoledronic acid was
approved for the prevention and treatment of GIO. In a
multicenter, double-blind, double-dummy, randomized
controlled trial that included 833 patients, a single 5 mg
intravenous infusion of zoledronic caused a greater increase
in bone mineral density than oral risedronate at 5 mg
daily.
73 Bisphosphonate treatment is recommended while
patients are on glucocorticoids; however, in subjects with
significant bone loss, therapy may need to be continued
following the discontinuation of glucocorticoids.
Caution needs to be exercised when considering the use
of bisphosphonates in women of childbearing age with
GIO,
63,74,75 given that bisphosphonates have an extended
half-life and may cross the placenta with potentially
unfavorable effects on fetal skeletal development. A recent
review of 51 human cases examining exposure to bispho-
sphonates before or during pregnancy did not demonstrate
skeletal abnormalities or other congenital malformations in
the infants.
75 Similarly, a related case-controlled study
suggested that preconceptional and first-trimester use of
bisphosphonates may pose limited fetal risk.
76 Nevertheless,
these studies included a small number of subjects and the
safety of bisphosphonates in women of childbearing age,
during pregnancy or while lactating is unknown. Therefore,
physicians should carefully weigh the risks and benefits of
bisphosphonate therapy in premenopausal women.
Although the guidelines do not address the use of
anabolic therapies in GIO, this approach appears to be ideal
because glucocorticoids reduce bone formation. Saag et al.,
published a randomized multicenter trial to compare use of
oral alendronate (10 mg/day) and subcutaneous teripara-
tide (20 mg/day) over 18 months in patients with established
GIO. The study showed that among patients with osteo-
porosis with a high risk for fracture, the bone mineral
density increase in patients receiving teriparatide was
greater than in those receiving alendronate.
77 The study
did not possess enough statistical power to detect differ-
ences in the incidence of fractures, although the number of
vertebral fractures was significantly lower in the teripara-
tide arm than in the alendronate arm. Subsequently, the
study was extended to 36 months and these results
confirmed a higher increase in bone mineral density and
fewer new vertebral fractures in subjects treated with
teriparatide as compared to alendronate.
78
CONCLUSION
After an extensive review of the literature, it was
observed that the frequency of GIO varies due to different
study designs and the lack of a uniform definition of GIO.
Similarly, currently available guidelines use different
recommendations for the prevention and treatment of
GIO, thereby creating practical difficulties. Consequently,
patients who are frequently exposed to GCs are not assessed
or treated.
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